

28. Rubin MA, Kleter B, Zhou M, et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. *Am J Pathol.* 2001; 159: 1211–1218.
29. Gunia S, Erbersdobler A, Hakenberg OW, et al. p16(INK4a) is a marker of good prognosis for primary invasive penile squamous cell carcinoma: a multi-institutional study. *J Urol.* 2012; 187(3): 899–907.
30. Ferrándiz-Pulido C, Masferrer E, de Torres I, et al. Identification and genotyping of human papillomavirus in a Spanish cohort of penile squamous cell carcinomas: correlation with pathologic subtypes, p16(INK4a) expression, and prognosis. *J Am Acad Dermatol.* 2013; 68(1): 73–82.
31. Steinestel J, Al Ghazal A, Arndt A, et al. The role of histologic subtype, p16(INK4a) expression, and presence of human papillomavirus DNA in penile squamous cell carcinoma. *BMC Cancer.* 2015; 15: 220.
32. Tang DH, Clark PE, Giannico G, et al. Lack of P16ink4a over expression in penile squamous cell carcinoma is associated with recurrence after lymph node dissection. *J Urol.* 2015; 193(2): 519–525.
33. Ueno H, Murphy J, Jass JR, et al. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. *Histopathology.* 2002; 40(2): 127–132.
34. Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. *Mod Pathol.* 2017; 30(9): 1299–1311.
35. Derani H, Becker AS, Hakenberg O, Erbersdobler A. Evaluation of the cellular dissociation grading, based on tumour budding and cell nest size, in squamous cell carcinoma of the penis. *Cancers (Basel).* 2022; 14: 4949.
36. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? *Lancet.* 2001; 357(9255): 539–545.
37. Pagès F, Galon J, Dieu-Nosjean MC, et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. *Oncogene.* 2010; 29(8): 1093–1102.
38. Liu Y, Liu Z, Yang Y, et al. The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer. *Br J Cancer.* 2023; 129(7): 1041–1049.
39. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. *J Pathol.* 2014; 232(2): 199–209.
40. Ottenhof SR, Djajadiningrat RS, Thygesen HH, et al. The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma. *Front Immunol.* 2018; 9: 1253.
41. Clark WH Jr, Elder DE, Guerry D 4<sup>th</sup>, et al. Model predicting survival in stage I melanoma based on tumor progression. *J Natl Cancer Inst.* 1989; 81(24): 1893–1904.
42. Yervoy FDA approval history. (citované 08. 03. 2024). Available from: <https://www.drugs.com/history/yervoy.html>.
43. Hrudka J, Hojný J, Prouzová Z, et al. High tumour mutational burden is associated with strong PD-L1 expression, HPV negativity, and worse survival in penile squamous cell carcinoma: an analysis of 165 cases. *Pathology.* 2024; 56(3): 357–366.
44. Kopecký J. Potenciální checkpoint inhibitory využitelné v léčbě nádorů. *Onkologie.* 2022; 16(3): 115–117.
45. Elst L, Philips G, Vandermaesen K, et al. Single-cell Atlas of Penile Cancer Reveals TP53 Mutations as a Driver of an Aggressive Phenotype, Irrespective of Human Papillomavirus Status, and Provides Clues for Treatment Personalization. *Eur Urol.* 2024; Apr 25: S0302–2838(24)02266–8. Epub ahead of print. PMID: 38670879.
46. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? *Ann Intern Med.* 1969; 71(4): 747–752.
47. Parrales A, Iwakuma T. Targeting Oncogenic Mutant p53 for Cancer Therapy. *Front Oncol.* 2015; 5: 288.
48. Prapiska FF, Warli SM. P53 and survival rate in penile cancer. *Open Access Maced J Med Sci.* 2019; 7: 1170–1173.
49. Gunia S, Kakies C, Erbersdobler A, et al. Expression of p53, p21 and cyclin D1 in penile cancer: p53 predicts poor prognosis. *J Clin Pathol.* 2012; 65: 232–236.